Incretins in Cardiometabolic Medicine: Leveraging GLP-1, GIP, and Glucagon Receptor Agonism for Cardiovascular Risk Reduction
Cardiovascular medicine is currently witnessing a paradigm shift. For decades, the management of type 2 diabetes mellitus (T2DM) and obesity was siloed, with clinicians focusing…